Abstract
Artemisinin-based combination therapy (ACT) partner drugs, currently used in Ghana are lumefantrine, amodiaquine and piperaquine. Plasmodium falciparum isolates with reduced susceptibility to these partner drugs may affect treatment outcome. Mutations in pfmdr1 gene is linked to reduced parasite susceptibility to amodiaquine and lumefantrine. In addition, the potency of the partner drugs in vivo depends on the metabolism by the cytochrome P450 (CYP) enzyme in the host. Mutations in the CYP2C8 and CYP3A4 genes are linked to reduced metabolism of amodiaquine and lumefantrine in vitro, respectively. This study investigated the host and parasite genetic factors affecting the susceptibility of the malaria parasite to ACT partner drugs. Archived samples from 240 patients age ≤ 9 years participating in anti-malarial drug resistance survey in Ghana, and given artemether with lumefantrine (AL) or artesunate with amodiaquine (AA), were selected and analysed. Polymerase chain reaction (PCR) followed by Sanger sequencing was used to determine the polymorphisms in CYP2C8, CYP3A4 and pfmdr1 genes. For CYP3A4, all had wild type alleles, suggesting that the hosts are good metabolizers of lumefantrine. For CYP2C8 60% had wild type alleles, 35% ...Continue Reading
References
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Xue-Qing LiCollen M Masimirembwa
Oct 31, 2002·Advanced Drug Delivery Reviews·Jatinder K LambaKenneth E Thummel
Mar 24, 2005·European Journal of Clinical Pharmacology·I CavacoJ P Gil
Mar 25, 2005·American Journal of Human Genetics·Janis E WiggintonGoncalo R Abecasis
Aug 13, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Magnus Ingelman-Sundberg, Cristina Rodriguez-Antona
Mar 16, 2007·Clinical Pharmacology and Therapeutics·S ParikhD L Kroetz
May 1, 2007·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Gabrielle HolmgrenAnders Björkman
Jun 7, 2007·Tropical Medicine & International Health : TM & IH·Christin SisowathJosé P Gil
Nov 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Juliana Martha SáThomas E Wellems
Dec 4, 2009·BMC Medical Genetics·William KudziJeremy J Mills
Dec 17, 2009·Malaria Journal·Eva Maria HodelHans-Peter Beck
Apr 7, 2010·The Journal of Infectious Diseases·Sumiti VinayakVenkatachalam Udhayakumar
Apr 28, 2010·Antimicrobial Agents and Chemotherapy·Nanhua ChenQin Cheng
Sep 13, 2011·Clinical Proteomics·Alan Hb Wu
Sep 14, 2011·PloS One·Pedro Eduardo FerreiraJosé Pedro Gil
Jan 22, 2013·Pharmacology & Therapeutics·Ulrich M Zanger, Matthias Schwab
Nov 1, 2013·Malaria Journal·Nancy O DuahKwadwo A Koram
Jan 6, 2016·Malaria Journal·Benjamin AbuakuKwadwo Koram
Jul 5, 2017·Malaria Journal·Ritah F MutagondaEleni Aklillu
Sep 25, 2017·Malaria Journal·Kinanga KiacoDinora Lopes
Apr 21, 2018·Parasite : Journal De La Société Française De Parasitologie·Manel OujiFrançoise Benoit-Vical
May 4, 2018·Nature Communications·Selina BoppSarah K Volkman